Pneumococcal Infectious Disease
Conditions
Brief summary
An open clinical trial of a 23-valent pneumococcal polysaccharide vaccine (PPV23) developed by Sinovac Life Science Co., Ltd was conducted to evaluate the safety of Sinovac PPV23 in target population of individuals aged 2 years and above. All participants received 1 dose of PPV23 and self-selected whether to receive 1 dose of influenza vaccine at the same time.
Interventions
23-valent pneumococcal polysaccharide vaccine
BIOLOGICALInfluenza vaccine
Influenza vaccine
Sponsors
Sinovac Biotech Co., Ltd
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Have voluntarily and at their own expense received the 23-valent pneumococcal polysaccharide vaccine; * Participants and/or their guardians are able to understand and voluntarily participate in this study and sign an informed consent form; * Provide valid legal identification.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse reactions to 23-valent pneumonia vaccine within 0-28 days after single and combined vaccination. | 28 days after the vaccination |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events to 23-valent pneumonia vaccine within 0-28 days after single and combined vaccination. | 28 days after the vaccination |
| Incidence of adverse events to 23-valent pneumonia vaccine within 0-7 days after single and combined vaccination. | 7 days after the vaccination |
Countries
China
Outcome results
None listed